Montreal, Canada. September 4, 2012 – MethylGene Inc. (TSX:MYG) today announced that preclinical data for its novel, clinical-stage antifungal MGCD290, will be presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in San Francisco, California from September 9 to 12, 2012. This poster presentation will highlight the efficacy of MGCD290 when combined with fluconazole in a mouse model of systemic candidiasis.
MGCD290, an Oral Fungal Hos2 Inhibitor, Enhances the Antifungal Properties of Fluconazole following Multiple or Single Oral Dose Administration in Pre- and Post-Infection Settings
Date and Time: Tuesday September 11, 11:15 AM to 1:15 PM (PDT)
Session: Clinical Mycology II
Presentation No.: M-1711
Location: Exhibit Halls A-C
MGCD290 is a first-in-class, orally available, small molecule inhibitor of the fungal enzyme Hos2. Current antifungal therapies suffer from a number of shortcomings including gaps in the coverage of fungal pathogens, acquisition of resistance, toxicity and drug-drug interactions. MGCD290 is initially being developed as an adjunct or combination product with fluconazole, the most widely used triazole antifungal. In vitro, MGCD290 in combination with fluconazole reverses fluconazole resistance (primary and acquired) in a wide range of fungal species, including Candida glabrata. MGCD290 has completed multiple Phase I studies in healthy adult volunteers and has shown an excellent safety profile without drug-drug interactions, either as monotherapy or in combination with fluconazole. A randomized, controlled Phase II study in moderate to severe acute VVC is underway.
MethylGene Inc. (TSX:MYG) is a small molecule drug development company that is advancing two novel therapeutics for cancer and infectious disease in human clinical trials. The Company’s lead product candidates are: MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme that is currently in Phase II trials for vulvovaginal candidiasis, and MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase I/II clinical trials for solid tumor cancers. MethylGene owns all rights to its lead product candidates, and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.
Investor Relations Contact:
Joseph Walewicz, CFA
Vice President, Business & Corporate Development
Phone: 514-337-3333 ext. 373
The Trout Group LLC